Alliance Pharma PLC Completion of Acquisition and TVR (1937S)
22 June 2018 - 1:13AM
UK Regulatory
TIDMAPH
RNS Number : 1937S
Alliance Pharma PLC
21 June 2018
21 June 2018
Alliance Pharma plc
("Alliance" or the "Group")
Completion of Acquisition and Total Voting Rights
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
company, is pleased to announce that following today's admission of
37,362,638 new ordinary shares, it has completed the acquisition of
the Nizoral Rights. This follows the announcements made by the
Company on 19 June 2018 in relation to the Acquisition and
Placing.
The Company now has a total of 514,205,522 ordinary shares in
issue. The figure of 514,205,522 ordinary shares should be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Capitalised terms used but not defined in this announcement have
the same meanings as set out in the announcement of the Company
released at 7.00 a.m. BST on 19 June 2018.
For further information:
Alliance Pharma plc Tel: +44 (0) 1249 466 966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
/ Freddie Naylor-Leyland
Corporate Broking: James Black
Investec Bank plc Tel: +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb / David
Herring
Buchanan Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma Mostyn-Owen
alliancepharma@buchanan.uk.com
Notes to editors
Alliance Pharma plc is an international specialty pharmaceutical
company.
Headquartered in Chippenham, UK, Alliance commenced trading in
1998 and has been listed on AIM since 2003. Alliance has a strong
track record of acquiring established niche products and it
currently owns or licenses the rights to approximately 90
pharmaceutical and consumer healthcare products. It has sales in
more than 100 countries either directly via its affiliates or
through its selected network of distributor partners. Alliance
joined the AIM market of the London Stock Exchange in December 2003
and trades under the symbol APH.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACQSESFIFFASEFM
(END) Dow Jones Newswires
June 21, 2018 11:13 ET (15:13 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024